Skip to main content

Sijmen de Vries, Chief Executive Officer of Pharming, said: 

“This successful convertible bond issuance demonstrates strong support from investors and is a positive step for Pharming. Taking into consideration the upcoming maturity of our convertible bonds in January 2025, this issuance and repurchase strengthens our financial position while enhancing flexibility for the continued execution of our business strategy over the next several years.”

Cookies: This website uses cookies Check the cookies page for more information Accept Decline